Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"INO has had a number of successes clinically and marquee collaborations that have led to its market cap being what it is today." (5/20/15) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Ross Silver Moreá>
Companies Commented On
- ADMA Biologics Inc.
- Applied Genetic Technologies Corp.
- bluebird bio Inc.
- Can-Fite BioPharma Ltd.
- CTI BioPharma
- Fate Therapeutics Inc.
- Galena Biopharma Inc.
- Lion Biotechnologies
- MEI Pharma Inc.
- Neuralstem Inc.
- Ocata Therapeutics Inc.
- OncoSec Medical Inc.
- Oncothyreon Inc.
- Paratek Pharmaceuticals Inc.
- Peregrine Pharmaceuticals Inc.
- Raymond James
- RXi Pharmaceuticals Corp.
- Spark Therapeutics Inc.
- Sunesis Pharmaceuticals Inc.
- Synta Pharmaceuticals Corp.
- TG Therapeutics Inc.
- Threshold Pharmaceuticals Inc.
- Verastem Inc.
Dr. Reni Benjamin is a senior biotechnology analyst at Raymond James. His expertise focuses on companies in the oncology and stem cell sectors. Benjamin has been ranked among the top analysts for recommendation performance and earnings accuracy by StarMine, has been cited in a variety of sources including The Wall Street Journal, Bloomberg Businessweek, Financial Times and Smart Money, and has made appearances on Bloomberg television/radio and CNBC. He authored a chapter in "The Delivery of Regenerative Medicines and Their Impact on Healthcare," has presented at various regional and international conferences, and has been published in peer-reviewed journals. He his a past member of the UAB School of Health Professions' Deans Advisory Board. Prior to joining Raymond James, Benjamin was a managing director and senior biotechnology analyst at H.C. Wainwright, Burrill Securities and Rodman & Renshaw. He was also an associate analyst at Needham and Company. Benjamin earned his doctorate from the University of Alabama at Birmingham in biochemistry and molecular genetics by discovering and characterizing a novel gene implicated in germ cell development. He earned a bachelor's degree in biology from Allegheny College.
Raymond James Analyst Reni Benjamin: Regenerating Portfolios with Cell Therapies, Antibodies and Small Molecules (11/4/15) Reni Benjamin of Raymond James has watched biotechnology move into a new era in which cells and genes can be manipulated to produce true disease-modifying results. In this interview with The Life Sciences Report, Benjamin outlines the groundbreaking work being done by a number of companies with the potential to return multiples on investment over the next two to three years.
A Bull Run Hiccup: 2015 Small-Cap Biotech Watchlist Update (5/13/15) It's been four months since The Life Sciences Report's 2015 Small-Cap Biotech Watchlist was announced at the Biotech Showcase in San Francisco. The year is off to a bumpy start, though the rough ride is not predicated, necessarily, on individual company performance. Read on for highlights of the Watchlist's Q1/15 performance.
Watchlist Analysts Forecast Continued Blue Sky for Biotech Industry (1/29/15) For the last two years the biotech sector has experienced market-beating gains, even taking into account the industry-wide hiccup in early 2014. Can this trend continue? The five analysts who selected names for The Life Sciences Report's 2015 Small-Cap Biotech Watchlist spend their days considering this question; it comes into play with every recommendation they make. The topic came up in various contexts during the Watchlist panel at the 2015 Biotech Showcase: Here are four factors investors should consider as they move into 2015.
"Subsequent analysis of CANF's CF101 data shows promise in a certain subset of patients." (5/13/15) Can-Fite BioPharma Ltd. - The Life Sciences Report 2015 Small-Cap Biotech Watchlist Update with Reni Benjamin Moreá>
"MSB has a 1,700-patient phase 3 study in progress, evaluating Revascor in congestive heart failureŚclearly a big market." (12/12/13) Mesoblast Ltd. - The Life Sciences Report Interview with Reni Benjamin Moreá>